Advanced breast cancer management continues to evolve with data-driven insights and innovative therapies, offering new hope across HR+/HER2-, HER2+, and mTNBC subtypes. Real-world evidence (RWE), post-CDK4/6i treatment strategies, and the emerging role of Antibody-Drug Conjugates (ADCs) are transforming the treatment landscape with better personalization and precision.
To explore these evolving paradigms, Docplexus , in association with Pfizer and Indian Society of Medical and Pediatric Oncology (ISMPO), presents a high-impact virtual event – Oncosummit: Breast Cancer 2025 , on Saturday, 19th July 2025, from 5:30 PM to 8:00 PM IST . Join us as national and international oncology leaders discuss: Real-world insights in HR+/HER2- mBC Management strategies post CDK4/6 inhibitor progression Case-based decision-making in HER2+ and mTNBC The emerging promise of ADCs in reshaping advanced…
